Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

血管紧张素转换酶基因对老年痴呆症痴呆症的行为和心理症状的影响

卷 16, 期 14, 2019

页: [1269 - 1275] 页: 7

弟呕挨: 10.2174/1567205017666200103114550

价格: $65

摘要

背景：血管紧张素转换酶（ACE）基因可能在调节β淀粉样蛋白（Aβ）降解中起着重要作用，但在影响阿尔茨海默氏病（AD）患者的认知和精神症状方面却发挥了作用尚待阐明。 目的：本研究旨在探讨ACE基因是否是AD人群痴呆行为和心理症状（BPSD）的危险因素。 方法：在360例临床诊断为AD的患者中，确定ACE和载脂蛋白E基因与等位基因ε4（APOEε4）的基因型。每年通过神经精神病学调查表（NPI）评估BPSD的症状和严重程度。 结果：在患者招募第一年的基础测量中，NPI评分没有明显的危险因素。在两年的随访中，ACE插入多态性显示NPI总评分进展的显着风险（校正比值比= 1.65，95％CI = 1.1- 2.5，p = 0.019）。 结论：ACE基因参与AD患者BPSD的加重。

关键词: 阿尔茨海默氏病，血管紧张素转换酶基因，载脂蛋白E基因，痴呆的行为和心理症状，神经精神病学目录，β-淀粉样蛋白。

« Previous Next »
[1]
Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 8(3): 497-500. (1996)
[http://dx.doi.org/10.1017/S1041610297003943] [PMID: 9154615]
[2]
Ferreira ST, Klein WL. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol Learn Mem 96(4): 529-43. (2011)
[http://dx.doi.org/10.1016/j.nlm.2011.08.003] [PMID: 21914486]
[3]
Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, et al. Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes. Am J Pathol 172(6): 1683-92. (2008)
[http://dx.doi.org/10.2353/ajpath.2008.070829] [PMID: 18467692]
[4]
Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Co-occurrence of Alzheimer’s disease ß-amyloid and τ pathologies at synapses. Neurobiol Aging 31(7): 1145-52. (2010)
[http://dx.doi.org/10.1016/j.neurobiolaging.2008.07.021] [PMID: 18771816]
[5]
Li K, Wei Q, Liu FF, Hu F, Xie AJ, Zhu LQ, et al. Synaptic dysfunction in alzheimer’s disease: Aβ, tau, and epigenetic alterations. Mol Neurobiol 55(4): 3021-32. (2018)
[http://dx.doi.org/10.1007/s12035-017-0533-3] [PMID: 28456942]
[6]
DeMichele-Sweet MA, Sweet RA. Genetics of Psychosis in Alzheimer Disease. Curr Genet Med Rep 2(1): 30-8. (2014)
[http://dx.doi.org/10.1007/s40142-014-0030-1] [PMID: 24883238]
[7]
Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer’s disease. Am J Epidemiol 162(4): 305-17. (2005)
[http://dx.doi.org/10.1093/aje/kwi202] [PMID: 16033878]
[8]
Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI, et al. The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease. Alzheimers Res Ther 6(3): 27. (2014)
[http://dx.doi.org/10.1186/alzrt257] [PMID: 24987467]
[9]
Barnes JM, Barnes NM, Costall B, Horovitz ZP, Ironside JW, Naylor RJ, et al. Angiotensin II inhibits cortical cholinergic function: implications for cognition. J Cardiovasc Pharmacol 16(2): 234-8. (1990)
[http://dx.doi.org/10.1097/00005344-199008000-00009] [PMID: 1697379]
[10]
Chou PS, Wu MN, Chou MC, Chien I, Yang YH. Angiotensin-converting enzyme insertion/deletion polymorphism and the longitudinal progression of Alzheimer’s disease. Geriatr Gerontol Int 17(10): 1544-50. (2017)
[PMID: 27862810]
[11]
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7): 939-44. (1984)
[http://dx.doi.org/10.1212/WNL.34.7.939] [PMID: 6610841]
[12]
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-98. (1975)
[http://dx.doi.org/10.1016/0022-3956(75)90026-6] [PMID: 1202204]
[13]
Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 6(1): 45-58. (1994)
[http://dx.doi.org/10.1017/S1041610294001602] [PMID: 8054493]
[14]
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12): 2308-14. (1994)
[http://dx.doi.org/10.1212/WNL.44.12.2308] [PMID: 7991117]
[15]
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43(11): 2412-4. (1993)
[http://dx.doi.org/10.1212/WNL.43.11.2412-a] [PMID: 8232972]
[16]
Yang YH, Fuh JL, Mok VC. Vascular contribution to cognition in stroke and Alzheimer’s disease. Brain Sci Adv 4: 39-48. (2018)
[http://dx.doi.org/10.26599/BSA.2018.9050001]
[17]
Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 20(6): 1433. (1992)
[http://dx.doi.org/10.1093/nar/20.6.1433-a] [PMID: 1313972]
[18]
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86(4): 1343-6. (1990)
[http://dx.doi.org/10.1172/JCI114844] [PMID: 1976655]
[19]
Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 332(11): 706-11. (1995)
[http://dx.doi.org/10.1056/NEJM199503163321103] [PMID: 7854377]
[20]
Zuo L, van Dyck CH, Luo X, Kranzler HR, Yang BZ, Gelernter J. Variation at APOE and STH loci and Alzheimer’s disease. Behav Brain Funct 2: 13. (2006)
[http://dx.doi.org/10.1186/1744-9081-2-13] [PMID: 16603077]
[21]
Rohn TT. Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer’s disease. Int J Mol Sci 14(7): 14908-22. (2013)
[http://dx.doi.org/10.3390/ijms140714908] [PMID: 23867607]
[22]
Ballard C, Massey H, Lamb H, Morris C. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry 63(2): 273-4. (1997)
[http://dx.doi.org/10.1136/jnnp.63.2.273b] [PMID: 9285479]
[23]
Harwood DG, Barker WW, Ownby RL, St George-Hyslop P, Duara R. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer’s disease. Am J Geriatr Psychiatry 7(2): 119-23. (1999)
[http://dx.doi.org/10.1097/00019442-199905000-00004] [PMID: 10322238]
[24]
Cao QY, Guo WH, Yang HL, Shen DW, Zhao P, Jiang KD, et al. Change of cerebral metabolism rate of glucose of cerebral white matter in Alzheimer’s disease: a study with statistical parametric mapping software. Zhonghua Yi Xue Za Zhi 87(39): 2777-9. (2007)
[PMID: 18167271]
[25]
Tian J, Shi J, Bailey K, Mann DM. Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer’s disease. Neuropathol Appl Neurobiol 30(1): 46-56. (2004)
[http://dx.doi.org/10.1046/j.0305-1846.2003.00510.x] [PMID: 14720176]
[26]
Rutten-Jacobs LC, de Leeuw FE, Geurts-van Bon L, Gordinou de Gouberville MC, Schepens-Franke AN, Dederen PJ, et al. White matter lesions are not related to β-amyloid deposition in an autopsy-based study. Curr Gerontol Geriatr Res 2011826862 (2011)
[http://dx.doi.org/10.1155/2011/826862] [PMID: 22203842]
[27]
Tian J, Shi J, Bailey K, Harris JM, Pritchard A, Lambert JC, et al. A polymorphism in the angiotensin 1-converting enzyme gene is associated with damage to cerebral cortical white matter in Alzheimer’s disease. Neurosci Lett 354(2): 103-6. (2004)
[http://dx.doi.org/10.1016/j.neulet.2003.09.072] [PMID: 14698449]
[28]
Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer’s disease. Curr Alzheimer Res 12(1): 32-46. (2015)
[http://dx.doi.org/10.2174/1567205012666141218140953] [PMID: 25523424]
[29]
Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer’s disease. Eur J Pharmacol 200(2-3): 289-92. (1991)
[http://dx.doi.org/10.1016/0014-2999(91)90584-D] [PMID: 1664329]
[30]
Shaw S, Bencherif M, Marrero MB. Angiotensin II blocks nicotine-mediated neuroprotection against beta-amyloid (1-42) via activation of the tyrosine phosphatase SHP-1. J Neurosci 23(35): 11224-8. (2003)
[http://dx.doi.org/10.1523/JNEUROSCI.23-35-11224.2003] [PMID: 14657181]
[31]
Barnes JM, Barnes NM, Costall B, Horovitz ZP, Ironside JW, Naylor RJ, et al. Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition. Brain Res 507(2): 341-3. (1990)
[http://dx.doi.org/10.1016/0006-8993(90)90294-L] [PMID: 2337775]
[32]
Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 63(7): 1324-5. (2004)
[http://dx.doi.org/10.1212/01.WNL.0000140705.23869.E9] [PMID: 15477567]
[33]
Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, et al. Angiotensin-converting enzyme levels and activity in Alzheimer’s disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 1(2): 163-77. (2009)
[PMID: 19956428]
[34]
Wu SJ, Hsieh TJ, Kuo MC, Tsai ML, Tsai KL, Chen CH, et al. Functional regulation of Alu element of human angiotensin-converting enzyme gene in neuron cells. Neurobiol Aging 34(7): 1921.e1-7. (2013)
[http://dx.doi.org/10.1016/j.neurobiolaging.2013.01.003] [PMID: 23391425]
[35]
Miners JS, van Helmond Z, Raiker M, Love S, Kehoe PG. ACE variants and association with brain Aβ levels in Alzheimer’s disease. Am J Transl Res 3(1): 73-80. (2010)
[PMID: 21139807]
[36]
Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 11(2): 131-45. (2003)
[http://dx.doi.org/10.1097/00019442-200303000-00004] [PMID: 12611743]
[37]
Wright JW, Harding JW. Brain renin-angiotensin--a new look at an old system. Prog Neurobiol 95(1): 49-67. (2011)
[http://dx.doi.org/10.1016/j.pneurobio.2011.07.001] [PMID: 21777652]
[38]
Tamano H, Ide K, Adlard PA, Bush AI, Takeda A. Involvement of hippocampal excitability in amyloid β-induced behavioral and psychological symptoms of dementia. J Toxicol Sci 41(4): 449-57. (2016)
[http://dx.doi.org/10.2131/jts.41.449] [PMID: 27432231]
[39]
Tana C, Wegener S, Borys E, Pambuccian S, Tchernev G, Tana M, et al. Challenges in the diagnosis and treatment of neurosarcoidosis. Ann Med 47(7): 576-91. (2015)
[http://dx.doi.org/10.3109/07853890.2015.1093164] [PMID: 26469296]
[40]
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet 383(9923): 1155-67. (2014)
[http://dx.doi.org/10.1016/S0140-6736(13)60680-7] [PMID: 24090799]
[41]
Tana C, Giamberardino MA, Di Gioacchino M, Mezzetti A, Schiavone C. Immunopathogenesis of sarcoidosis and risk of malignancy: a lost truth? Int J Immunopathol Pharmacol 26(2): 305-13. (2013)
[http://dx.doi.org/10.1177/039463201302600204] [PMID: 23755746]
[42]
Oliveira FF, Chen ES, Smith MC, Bertolucci PH. Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia. Br J Psychiatry 39(2): 95-103. (2017)
[http://dx.doi.org/10.1590/1516-4446-2016-1991] [PMID: 28099631]
[43]
Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimers Dement 11(6): 710-7. (2015)
[http://dx.doi.org/10.1016/j.jalz.2014.10.008] [PMID: 25510382]
[44]
de Oliveira FF, Bertolucci PH, Chen ES, Smith Mde A. Assessment of sleep satisfaction in patients with dementia due to Alzheimer’s disease. J Clin Neurosci 21(12): 2112-7. (2014)
[http://dx.doi.org/10.1016/j.jocn.2014.05.041] [PMID: 25194823]
[45]
Lyketsos CG, Baker L, Warren A, Steele C, Brandt J, Steinberg M, et al. Depression, delusions, and hallucinations in Alzheimer’s disease: no relationship to apolipoprotein E genotype. J Neuropsychiatry Clin Neurosci 9(1): 64-7. (1997)
[http://dx.doi.org/10.1176/jnp.9.1.64] [PMID: 9017530]
[46]
van der Flier WM, Staekenborg S, Pijnenburg YA, et al. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 23(1): 42-6. (2007)
[http://dx.doi.org/10.1159/000096682] [PMID: 17077632]

Rights & Permissions Print Cite
Article Metrics
22
© 2024 Bentham Science Publishers | Privacy Policy